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1. INTRODUCTION {#jcmm14486-sec-0001}
===============

As a leading cause of death worldwide, cancer is a big problem for human beings.[1](#jcmm14486-bib-0001){ref-type="ref"} It was reported that there were 14.1 million newly diagnosed cases and 8.2 million deaths resulted from poor prognosis and post‐operative care each year despite of advancement of cancer diagnosis and treatment.[1](#jcmm14486-bib-0001){ref-type="ref"}, [2](#jcmm14486-bib-0002){ref-type="ref"}, [3](#jcmm14486-bib-0003){ref-type="ref"} Therefore, novel biomarkers for predicting cancer prognosis were important and urgently needed for therapeutic decision‐making and improving the care after surgery.[4](#jcmm14486-bib-0004){ref-type="ref"}

Long non‐coding RNAs (lncRNAs), longer than 200 nucleotides in length, are mRNA‐like transcripts and cannot be translated into proteins.[5](#jcmm14486-bib-0005){ref-type="ref"}, [6](#jcmm14486-bib-0006){ref-type="ref"} It is being increasingly recognized that abnormal expression of lncRNAs is specifically related to tumorigenesis, tumour progression and metastasis.[7](#jcmm14486-bib-0007){ref-type="ref"}, [8](#jcmm14486-bib-0008){ref-type="ref"} As a kind of potential and novel cancer biomarker, there were more and more lncRNAs found every year. Although some lncRNAs functioned as protective genes, such as ANRIL, GAS5, MEG3,[9](#jcmm14486-bib-0009){ref-type="ref"}, [10](#jcmm14486-bib-0010){ref-type="ref"}, [11](#jcmm14486-bib-0011){ref-type="ref"} most act as oncogenes, such as HOTAIR, RMRP, CCAT2 and TUG1.[12](#jcmm14486-bib-0012){ref-type="ref"}, [13](#jcmm14486-bib-0013){ref-type="ref"}, [14](#jcmm14486-bib-0014){ref-type="ref"}, [15](#jcmm14486-bib-0015){ref-type="ref"} Therefore, although IncRNAs were known as the noise of transcriptions initially, increasing attentions were attached to them because of their important roles in development of diseases and diverse biological processes, and they may serve as promising biomarkers in predicting prognosis of cancer.[14](#jcmm14486-bib-0014){ref-type="ref"}, [15](#jcmm14486-bib-0015){ref-type="ref"}, [16](#jcmm14486-bib-0016){ref-type="ref"}

Gastric carcinoma highly expressed transcript 1 (GHET1), has been identified as an lncRNA recently. It has been confirmed to be an oncogene in a variety of cancers, including the hepatocellular carcinoma, gastric cancer and colorectal cancer. LncRNA GHET1 activated by H3K27 acetylation promotes cell tumorigenesis through regulating ATF1 in the hepatocellular carcinoma.[17](#jcmm14486-bib-0017){ref-type="ref"} Knockdown of lncRNA GHET1 inhibits cell‐cycle progression and invasion.[18](#jcmm14486-bib-0018){ref-type="ref"} Knockdown of lncRNA GHET1 inhibits cell proliferation and invasion of the colorectal cancer.[19](#jcmm14486-bib-0019){ref-type="ref"} Overexpression of lncRNA GHET1 promotes the development of multidrug resistance in the gastric cancer cells.[20](#jcmm14486-bib-0020){ref-type="ref"}

Despite some studies that reported the association between lncRNA GHET1 and cancers, there has been still no consistent conclusion on the prognostic value of lncRNA GHET1 in cancer patients because of different outcomes and limited sample size in each individual study.[17](#jcmm14486-bib-0017){ref-type="ref"}, [18](#jcmm14486-bib-0018){ref-type="ref"}, [19](#jcmm14486-bib-0019){ref-type="ref"}, [20](#jcmm14486-bib-0020){ref-type="ref"}, [21](#jcmm14486-bib-0021){ref-type="ref"}, [22](#jcmm14486-bib-0022){ref-type="ref"} Therefore, we conducted this meta‐analysis to identify the relationship between the expressions of lncRNA GHET1 in a variety of human cancers and the patients' overall survival (OS) as well as other clinical parameters, identifying the prognostic value of lncRNA GHET1 as a novel biomarker for human cancers.

2. MATERIALS AND METHODS {#jcmm14486-sec-0002}
========================

Our systematic review and meta‐analysis was reported according to the recommendations of the PRISMA statement.[23](#jcmm14486-bib-0023){ref-type="ref"}

2.1. Literature retrieval strategy {#jcmm14486-sec-0003}
----------------------------------

In order to collect all articles eligible for this study, we retrieved keywords in different databases, including PubMed, Embase, Web of Science, Cochrane Library and ClinicalTrials.gov from their inception to 26 November 2018. Keywords and MeSH terms were used in combination as follows: ('GHET1 transcript' OR 'gastric carcinoma high expressed transcript 1, human' OR 'lncRNA‐GHET1, human' OR 'gastric carcinoma proliferation enhancing transcript 1, human') AND ('cancer' OR 'tumour' OR 'neoplasm' OR 'carcinoma') AND ('pathology' OR 'pathological feature' OR 'prognosis' OR 'clinical outcome' OR 'survival'). Other additional studies were obtained by screening the reference list. The articles only written in English were included in this meta‐analysis.

2.2. Inclusion and exclusion criteria {#jcmm14486-sec-0004}
-------------------------------------

Eligible articles enrolled in this meta‐analysis meet the following criteria: (a) patients included were diagnosed with cancers; (b) the expression of lncRNA GHET1 in tissue specimens was reported; (c) the associations between lncRNA GHET1 expression and prognosis or clinical parameters of cancers were reported; (d) sufficient data were eligible to calculate the hazard ratio (HR) with 95% confidence intervals (CI) for OS, or odds ratios (ORs) with 95% CI for clinical parameter. (e) Language was used in English. Exclusion criteria were (included): (a) studies without available data for survival and clinical parameters; (b) overlapping data; or (c) letters, reviews, case reports and expert opinions.

2.3. Data extraction and quality assessment {#jcmm14486-sec-0005}
-------------------------------------------

Two authors extracted the information and data from included studies independently, and any disagreement was resolved by consulting with the third author. The information and data were as following: family name of first author, year of publication, cancer type, total sample size, tumour stage, sample type, cut‐off value of lncRNA GHET1, detection method, outcome measures, follow‐up time and type of analysis method. Meanwhile, some other clinical parameters were recorded, including gender, age, lymph node metastasis, TNM stage, differentiation, distant metastasis, tumour size and smoke history. For the HRs and 95% CIs of survival, the data were recorded directly from articles provided the detail information. Two individual authors extracted the data from those provided Kaplan‐Meier curves only with the Engauge Digitizer version 4.1. To evaluate the quality of included studies, the Newcastle‐Ottawa Scale (NOS) was applied, whose score is ranging from 0 to 9 points.[24](#jcmm14486-bib-0024){ref-type="ref"}, [25](#jcmm14486-bib-0025){ref-type="ref"} Studies' NOS score, 7‐9, has been regarded as high quality.

2.4. Statistical methods {#jcmm14486-sec-0006}
------------------------

Stata SE12.0 software (StataCorp LLC, College Station, Texas) was used to calculate the statistical analysis of HRs for OS and ORs for clinical parameters. Fixed‐effects model was used to pool data with statistical heterogeneity determined by the inconsistency index (*I* ^2^ ≥ 50%) and the chi‐squared test (*P* ≤ 0.10). If the statistical heterogeneity was significant, random‐effects model was then preformed.[26](#jcmm14486-bib-0026){ref-type="ref"}, [27](#jcmm14486-bib-0027){ref-type="ref"}, [28](#jcmm14486-bib-0028){ref-type="ref"}, [29](#jcmm14486-bib-0029){ref-type="ref"} In addition, we preformed Begg\'s rank correlation test to assess the publication bias for the HRs for OS, determined as positive by Pr\>\|z\|≤0.1. We also did a sensitivity analysis to check the stability of results for OS. Moreover, subgroup analyses of OS were performed.

3. RESULTS {#jcmm14486-sec-0007}
==========

3.1. Literature search {#jcmm14486-sec-0008}
----------------------

A total of 12 eligible articles containing 761 patients with cancers were included in this meta‐analysis after screening titles, abstracts or full texts.[18](#jcmm14486-bib-0018){ref-type="ref"}, [21](#jcmm14486-bib-0021){ref-type="ref"}, [22](#jcmm14486-bib-0022){ref-type="ref"}, [30](#jcmm14486-bib-0030){ref-type="ref"}, [31](#jcmm14486-bib-0031){ref-type="ref"}, [32](#jcmm14486-bib-0032){ref-type="ref"}, [33](#jcmm14486-bib-0033){ref-type="ref"}, [34](#jcmm14486-bib-0034){ref-type="ref"}, [35](#jcmm14486-bib-0035){ref-type="ref"}, [36](#jcmm14486-bib-0036){ref-type="ref"}, [37](#jcmm14486-bib-0037){ref-type="ref"}, [38](#jcmm14486-bib-0038){ref-type="ref"} The process of article selection was shown in Figure [1](#jcmm14486-fig-0001){ref-type="fig"}.

![Flow diagram of the literature retrieval and selection](JCMM-23-4891-g001){#jcmm14486-fig-0001}

3.2. Main information of included studies {#jcmm14486-sec-0009}
-----------------------------------------

In these studies, the sample size ranged from 42 to 105, among a total of 761 participants. The main characteristics of included studies were presented in Table [1](#jcmm14486-tbl-0001){ref-type="table"}. Among the 12 studies, there were various types of cancers, including non‐small cell lung cancer (two articles), hepatocellular carcinoma, bladder cancer, oesophageal squamous cell carcinoma, head and neck cancer, breast cancer (two articles), gastric cancer (three articles) and pancreatic cancer. Among these studies, one came from Iran, all others came from China. The publication period of these articles ranged from 2014 to 2018. The samples of all these studies were from cancer and matched normal tissues. In addition, the level of lncRNA GHET1 was detected by quantitative reverse transcription polymerase chain reaction (qRT‐PCR). There were four different cut‐off points for the 12 studies: four median level, four median ratio, one average level and three not reported. In regard to disease outcomes, eight studies reported OS, one study reported DFS, the remnant reported clinical parameters. The high‐quality studies in this meta‐analysis have NOS score: 7‐9.

###### 

The main information of included studies in the meta‐analysis

  References                                                   Country   Cancer type                           Samples （n）   Tumour stage   Sample type                         Cut‐off value   Detection method   Outcome measure   Follow‐up   Analysis method   NOS
  ------------------------------------------------------------ --------- ------------------------------------- --------------- -------------- ----------------------------------- --------------- ------------------ ----------------- ----------- ----------------- -----
  Xia et al[18](#jcmm14486-bib-0018){ref-type="ref"}           China     Gastric cancer                        42              I‐IV           Cancer and matched normal tissues   Median level    qRT‐PCR            CP                NR          NR                6
  Jin et al[21](#jcmm14486-bib-0021){ref-type="ref"}           China     Hepatocellular carcinoma              68              I‐IV           Cancer and matched normal tissues   Median level    qRT‐PCR            OS                5 y         Kaplan‐Meier      9
  Guan et al[22](#jcmm14486-bib-0022){ref-type="ref"}          China     Non‐small cell lung cancer            52              I‐III          Cancer and matched normal tissues   NR              qRT‐PCR            OS                55 mo       Multivariate      8
  Li et al[30](#jcmm14486-bib-0030){ref-type="ref"}            China     Bladder cancer                        80              NR             Cancer and matched normal tissues   Median ratio    qRT‐PCR            OS                5 y         Kaplan‐Meier      8
  Liu et al[31](#jcmm14486-bib-0031){ref-type="ref"}           China     Oesophageal squamous cell carcinoma   55              I‐IV           Cancer and matched normal tissues   Median ratio    qRT‐PCR            CP                NR          NR                6
  Liu & Wu[32](#jcmm14486-bib-0032){ref-type="ref"}            China     Head and neck cancer                  86              I‐III          Cancer and matched normal tissues   Median ratio    qRT‐PCR            OS                \>5         Kaplan‐Meier      8
  Sarrafzadeh et al[33](#jcmm14486-bib-0033){ref-type="ref"}   Iran      Breast cancer                         47              O‐IV           Cancer and matched normal tissues   Average level   qRT‐PCR            CP                NR          NR                7
  Shen et al[34](#jcmm14486-bib-0034){ref-type="ref"}          China     Non‐small cell lung cancer            105             I‐IV           Cancer and matched normal tissues   Median ratio    qRT‐PCR            OS                \>5 y       Kaplan‐Meier      9
  Song et al[35](#jcmm14486-bib-0035){ref-type="ref"}          China     Breast cancer                         60              I‐IV           Cancer and matched normal tissues   Median level    qRT‐PCR            OS                5 y         Kaplan‐Meier      8
  Yang et al[36](#jcmm14486-bib-0036){ref-type="ref"}          China     Gastric cancer                        42              I‐IV           Cancer and matched normal tissues   NR              qRT‐PCR            OS                40 mo       Kaplan‐Meier      7
  Zhou et al[37](#jcmm14486-bib-0037){ref-type="ref"}          China     Pancreatic cancer                     64              I‐IV           Cancer and matched normal tissues   Median level    qRT‐PCR            CP                NR          NR                7
  Yang et al[38](#jcmm14486-bib-0038){ref-type="ref"}          China     Osteosarcoma                          60              I‐IV           Cancer and matched normal tissues   NR              qRT‐PCR            OS                5 y         Kaplan‐Meier      7

Abbreviations: CP, clinical parameter; NR, not reported; OS, overall survival; qRT‐PCR, quantitative reverse‐transcriptase polymerase chain reaction.

John Wiley & Sons, Ltd

3.3. Association between lncRNA GHET1 expression and OS {#jcmm14486-sec-0010}
-------------------------------------------------------

Seven articles investigated the association between lncRNA GHET1 expression and OS with a total of 553 cancer patients.[21](#jcmm14486-bib-0021){ref-type="ref"}, [22](#jcmm14486-bib-0022){ref-type="ref"}, [30](#jcmm14486-bib-0030){ref-type="ref"}, [32](#jcmm14486-bib-0032){ref-type="ref"}, [34](#jcmm14486-bib-0034){ref-type="ref"}, [35](#jcmm14486-bib-0035){ref-type="ref"}, [36](#jcmm14486-bib-0036){ref-type="ref"}, [38](#jcmm14486-bib-0038){ref-type="ref"} We used fix‐effect model to analysis the HR of OS because of no significant heterogeneity among studies (*I* ^2^ = 0.0%, *P* = 0.842; Figure [2](#jcmm14486-fig-0002){ref-type="fig"}). Meta‐analysis of these studies revealed that high lncRNA GHET1 expression level was significantly relative to poor OS in human cancer (HR: 2.30, 95% CI: 1.75‐3.02). Then we performed subgroup meta‐analysis, which was stratified by analysis type, cancer type, sample size and follow‐up time (Table [2](#jcmm14486-tbl-0002){ref-type="table"}). We found that high lncRNA GHET1 expression level was positively associated with shorter OS in studies using multivariate analysis method (HR: 2.49, 95% CI: 1.51‐4.10) and non‐multivariate (HR: 2.23, 95% CI: 1.61‐3.08). In addition, significant association was also found in subgroup meta‐analysis stratified by cancer type. The HRs for the high lncRNA GHET1 expression group versus the low lncRNA GHET1 expression group were 2.63 (95% CI: 1.47‐4.73) in digestive system cancer and 2.22 (95% CI: 1.63‐3.02) in other cancers. After stratified by sample size, the HRs were 2.35 (95% CI: 1.72‐3.21) in studies containing the number of patients \<100 and 2.15 (95% CI: 1.23‐3.76) in studies with the number of patients ≥100. After stratification by follow‐up time, the HRs were 2.24 (95% CI: 1.60‐3.12) in studies with follow‐up time ≥5 years and 2.44 (95% CI: 1.51‐3.95) when follow‐up time was \<5 years (Figure [3](#jcmm14486-fig-0003){ref-type="fig"}).

![Meta‐analysis of the pooled hazard ratios (HRs) of overall survival in patients with cancer](JCMM-23-4891-g002){#jcmm14486-fig-0002}

###### 

The results of subgroup analyses of OS

  Variables          Studies (n)        Number of patients (n)   HR     95% CI      *I^2^* (%)   *P* ~h~   Model   
  ------------------ ------------------ ------------------------ ------ ----------- ------------ --------- ------- -------
  Analysis type      Multivariate       1                        52     2.49        1.51‐4.10    ---       ---     Fixed
  Non‐multivariate   7                  501                      2.23   1.61‐3.08   0            0.770     Fixed   
  Cancer type        Digestive system   3                        170    2.63        1.47‐4.73    22.2      0.277   Fixed
  Others             5                  383                      2.22   1.63‐3.02   0            0.963     Fixed   
  Sample size        \<100              7                        448    2.35        1.72‐3.21    0         0.763   Fixed
  ≥100               1                  105                      2.15   1.23‐3.76   ---          ---       Fixed   
  Follow‐up time     ≥5 y               6                        459    2.24        1.60‐3.12    0         0.657   Fixed
  \<5 y              2                  94                       2.44   1.51‐3.95   0            0.798     Fixed   

Abbreviation: CI, confidence interval; HR, hazard ratios; OS, overall survival.

John Wiley & Sons, Ltd

![Forest plots of hazard ratios (HRs) for the relationship between high Musashi‐1 expression and overall survival (OS): (A) stratified by analysis type; (B) stratified by cancer type; (C) stratified by sample size; (D) stratified by follow‐up time](JCMM-23-4891-g003){#jcmm14486-fig-0003}

3.4. Association between lncRNA GHET1 expression and clinical parameters {#jcmm14486-sec-0011}
------------------------------------------------------------------------

According to meta‐analysis results of Table [3](#jcmm14486-tbl-0003){ref-type="table"}, we found that the high expression of lncRNA GHET1 was associated with more advanced clinical stage (OR = 3.23, 95% CI: 2.25‐4.64), earlier lymph node metastasis (OR = 3.19, 95% CI: 1.85‐5.48), earlier distant metastasis (OR = 4.65, 95% CI: 1.99‐10.83) and bigger tumour size (OR = 2.95, 95% CI: 1.78‐4.89) (Figure [4](#jcmm14486-fig-0004){ref-type="fig"}). However, no statistical significance was found in gender (OR = 0.98, 95% CI: 0.69‐1.38), age (OR = 0.83, 95% CI:0.57‐1.21), differentiation (OR = 1.32, 95% CI: 0.67‐2.60) (Figure [5](#jcmm14486-fig-0005){ref-type="fig"}).

###### 

Meta‐analysis of the relationship between over‐expressed LncRNA GHET1 and clinical parameters

  Categories                        Studies (n)   Number of patients (n)   OR     95% CI       Heterogeneity   Model   
  --------------------------------- ------------- ------------------------ ------ ------------ --------------- ------- --------
  Gender (male versus female)       9             574                      0.98   0.69‐1.38    0               0.848   Fixed
  Age (\>60 vs \<60 y)              8             469                      0.83   0.57‐1.21    0               0.966   Fixed
  TNM stage (III/IV vs I/II)        8             529                      3.23   2.25‐4.64    0               0.662   Fixed
  LNM (yes vs no)                   9             549                      3.19   1.85‐5.48    47.8            0.053   Random
  Distant metastasis (yes vs no)    4             208                      4.65   1.99‐10.83   0               0.789   Fixed
  Differentiation (poor vs good)    7             388                      1.32   0.67‐2.60    55.8            0.035   Random
  Tumour size (bigger vs smaller)   8             574                      2.95   1.78‐4.89    45.5            0.065   Random

Abbreviations: CI, confidence interval; lncRNA, long non‐coding RNA; LNM, lymph node metastasis; OR, odds ratio.

John Wiley & Sons, Ltd

![Forest plots of odds ratios (ORs) for the relationship between high Musashi‐1 expression and clinical parameters: (A) TNM stage; (B) lymph node metastasis; (C) distant metastasis; (D) tumour size](JCMM-23-4891-g004){#jcmm14486-fig-0004}

![Forest plots of odds ratios (ORs) for the relationship between high Musashi‐1 expression and clinical parameters: (A) gender; (B) age; (C) differentiation](JCMM-23-4891-g005){#jcmm14486-fig-0005}

3.5. Publication bias {#jcmm14486-sec-0012}
---------------------

No obvious bias was detected by the funnel plot (Figure [6](#jcmm14486-fig-0006){ref-type="fig"}) and Begg\'s test in HRs for OS (*P* = 1.000). We did not proceed Begg\'s test for other clinical parameters, because of no enough studies included (n \< 10).

![Funnel plot of the publication bias for the analysis of the pooled HRs of OS](JCMM-23-4891-g006){#jcmm14486-fig-0006}

3.6. Sensitivity analysis {#jcmm14486-sec-0013}
-------------------------

Sensitivity analysis was performed by removing one study every time from the pooled analysis to check the stability of results for OS of each study (Figure [7](#jcmm14486-fig-0007){ref-type="fig"}).

![Sensitivity analysis of the pooled HRs of lncRNA GHET1 expression and OS](JCMM-23-4891-g007){#jcmm14486-fig-0007}

4. DISCUSSION {#jcmm14486-sec-0014}
=============

As lncRNAs play important roles in the process of genes' transcription and translation, their dysregulation has been increasingly identified as a hallmark feature in the progression of cancer. GHET1, a novel identified lncRNA, was significantly over‐expressed in the gastric cancer.[36](#jcmm14486-bib-0036){ref-type="ref"} It has been confirmed to be an oncogene through some biological process in a variety of cancers although the role of GHET1 in cancers remains unclear yet.[17](#jcmm14486-bib-0017){ref-type="ref"}, [21](#jcmm14486-bib-0021){ref-type="ref"}, [31](#jcmm14486-bib-0031){ref-type="ref"}, [35](#jcmm14486-bib-0035){ref-type="ref"} In addition, the prognosis value of GHET1 expression in cancer and association between high expression of GHET1 and tumour stage, differentiation, has also been widely reported.[21](#jcmm14486-bib-0021){ref-type="ref"}, [22](#jcmm14486-bib-0022){ref-type="ref"}, [30](#jcmm14486-bib-0030){ref-type="ref"}

In our meta‐analysis, we found that lncRNA GHET1 might be an unfavourable prognosis factor for cancer patients. Higher expression of GHET1 was associated with poorer OS (HR = 2.30, 95% CI: 1.75‐3.02), and the subgroup meta‐analysis stratified by analysis type, cancer type, sample size and follow‐up time showed the similar results. Furthermore, no heterogeneity was found in the association between GHET1 expression and OS. In addition, we explored the relationship between GHET1 expression and clinical parameters. We found that there was a significant positive correlation between higher GHET1 expression level and more advanced clinical stage (OR = 3.23, 95% CI: 2.25‐4.64), earlier lymph node metastasis (OR = 3.19, 95% CI: 1.85‐5.48), earlier distant metastasis (OR = 4.65, 95% CI: 1.99‐10.83) and bigger tumour size (OR = 2.95, 95% CI: 1.78‐4.89). Collectively, lncRNA GHET1 participates in the development and progression of tumours and may serve as a promising biomarker for prognosis in Asian with cancers.

A few highlights exist in our study. Firstly, this is the first study comprehensively explored the relationship between the GHET1 expression level and prognostic outcomes in human cancers based on our knowledge. Secondly, the methodology and results are credible as we followed recommendations of the PRISMA statement.[23](#jcmm14486-bib-0023){ref-type="ref"} Furthermore, the results are relatively accurate because of a fixed‐effect model used in most of our analysis.

However, there are some limitations in our meta‐analysis. First, the number of patients included was relatively small, which might lead to inadequate stringency. Second, all studies included were retrospective studies. Most of them were from China, which may be more preferential in China. Third, the cut‐off values for positive GHET1 expression were not always consistent in different studies. However, all of them can reflect the tendency of GHET1 expression and no statistical heterogeneity was found among them, including publication bias analysis and sensitivity analysis. Fourth, the HRs and 95% CIs of several studies were extracted from Kaplan‐Meier curves, which might affect the accuracy of consequences.

In conclusion, the higher lncRNA GHET1 expression was associated with more advanced clinical stage, earlier lymph node metastasis, earlier distant metastasis, bigger tumour size and poorer OS in cancer patients. Our meta‐analysis suggested that lncRNA GHET1 may serve as a promising biomarker for prognosis in Asian with cancers. In the future, multicentre, larger and higher‐quality studies using single standard for determining GHET1 expression are needed to identify the results of this study.
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